Free Trial
→ Inside the Options Play With a High Historical Win Rate (From TradeWins) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.98 +0.00 (+0.20%)
As of 10/7/2026 11:55 AM Eastern
Compare

BPCR vs. ASLI, LGT, RIV, SGEM, and FWT

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include abrdn European Logistics Income (ASLI), Lighthouse Group (LGT), River and Mercantile Group (RIV), ScotGems (SGEM), and Foresight Technology VCT (FWT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does BioPharma Credit compare to abrdn European Logistics Income?

BioPharma Credit (LON:BPCR) and abrdn European Logistics Income (LON:ASLI) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

31.3% of BioPharma Credit shares are owned by institutional investors. Comparatively, 6.3% of abrdn European Logistics Income shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.1% of abrdn European Logistics Income shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioPharma Credit has a beta of 0.22688746, indicating that its stock price is 77% less volatile than the broader market. Comparatively, abrdn European Logistics Income has a beta of 0.854, indicating that its stock price is 15% less volatile than the broader market.

In the previous week, BioPharma Credit had 3 more articles in the media than abrdn European Logistics Income. MarketBeat recorded 3 mentions for BioPharma Credit and 0 mentions for abrdn European Logistics Income. BioPharma Credit's average media sentiment score of 1.10 beat abrdn European Logistics Income's score of 0.59 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
abrdn European Logistics Income Positive

BioPharma Credit has higher revenue and earnings than abrdn European Logistics Income. abrdn European Logistics Income is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
abrdn European Logistics Income-£15.46M-2.82-£79.93M-£5.80N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. abrdn European Logistics Income pays an annual dividend of GBX 8.92 per share and has a dividend yield of 84.5%. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. abrdn European Logistics Income pays out -153.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has a net margin of 89.20% compared to abrdn European Logistics Income's net margin of -214.42%. BioPharma Credit's return on equity of 9.39% beat abrdn European Logistics Income's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
abrdn European Logistics Income -214.42%-19.46%1.88%

Summary

BioPharma Credit beats abrdn European Logistics Income on 13 of the 15 factors compared between the two stocks.

How does BioPharma Credit compare to Lighthouse Group?

BioPharma Credit (LON:BPCR) and Lighthouse Group (LON:LGT) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

BioPharma Credit has a net margin of 89.20% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
Lighthouse Group N/A N/A N/A

In the previous week, BioPharma Credit had 3 more articles in the media than Lighthouse Group. MarketBeat recorded 3 mentions for BioPharma Credit and 0 mentions for Lighthouse Group. BioPharma Credit's average media sentiment score of 1.10 beat Lighthouse Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
Lighthouse Group Neutral

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
Lighthouse Group£53.42M0.00N/A£1.80N/A

31.3% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BioPharma Credit beats Lighthouse Group on 10 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

River and Mercantile Group (LON:RIV) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioPharma Credit has a net margin of 89.20% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
River and Mercantile GroupN/A N/A N/A
BioPharma Credit 89.20%9.39%4.98%

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
River and Mercantile Group£74.82M0.00N/A-£2.20N/A
BioPharma Credit£110.03M0.10£10.42B£9.540.10

In the previous week, BioPharma Credit had 3 more articles in the media than River and Mercantile Group. MarketBeat recorded 3 mentions for BioPharma Credit and 0 mentions for River and Mercantile Group. BioPharma Credit's average media sentiment score of 1.10 beat River and Mercantile Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
River and Mercantile Group Neutral
BioPharma Credit Positive

River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BioPharma Credit beats River and Mercantile Group on 11 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

BioPharma Credit (LON:BPCR) and ScotGems (LON:SGEM) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 714.3%. ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays out 73.4% of its earnings in the form of a dividend. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
ScotGems£5.07M0.00N/A£0.07N/A

BioPharma Credit has a net margin of 89.20% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 9.39% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
ScotGems N/A N/A N/A

31.3% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, BioPharma Credit had 3 more articles in the media than ScotGems. MarketBeat recorded 3 mentions for BioPharma Credit and 0 mentions for ScotGems. BioPharma Credit's average media sentiment score of 1.10 beat ScotGems' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
ScotGems Neutral

Summary

BioPharma Credit beats ScotGems on 11 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to Foresight Technology VCT?

BioPharma Credit (LON:BPCR) and Foresight Technology VCT (LON:FWT) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

BioPharma Credit has a net margin of 89.20% compared to Foresight Technology VCT's net margin of -76.81%. BioPharma Credit's return on equity of 9.39% beat Foresight Technology VCT's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit89.20% 9.39% 4.98%
Foresight Technology VCT -76.81%-1.24%3.17%

BioPharma Credit has higher revenue and earnings than Foresight Technology VCT. Foresight Technology VCT is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£110.03M0.10£10.42B£9.540.10
Foresight Technology VCT£64K649.70£23.15M-£0.80N/A

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.3% of Foresight Technology VCT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BioPharma Credit had 3 more articles in the media than Foresight Technology VCT. MarketBeat recorded 3 mentions for BioPharma Credit and 0 mentions for Foresight Technology VCT. BioPharma Credit's average media sentiment score of 1.10 beat Foresight Technology VCT's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Positive
Foresight Technology VCT Neutral

BioPharma Credit has a beta of 0.22688746, indicating that its share price is 77% less volatile than the broader market. Comparatively, Foresight Technology VCT has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Summary

BioPharma Credit beats Foresight Technology VCT on 11 of the 13 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£11.00M£5.16B£13.42B£2.79B
Dividend Yield7.11%7.58%6.04%6.21%
P/E Ratio0.1030.1824.76367.41
Price / Sales0.101,217.03490.5089,142.88
Price / Cash1.1947.6945.2427.89
Price / Book0.013.472.696.74
Net Income£10.42B£415.67M£1.32B£5.89B
7 Day Performance0.20%-0.34%-0.37%-0.21%
1 Month Performance1.66%-2.64%-3.16%-1.09%
1 Year Performance8.89%9.82%9.56%22.65%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.98
+0.2%		N/A+7.9%£11.00M£110.03M0.10N/A
ASLI
abrdn European Logistics Income
N/AGBX 10.50
-4.7%		N/A-68.3%£43.28M-£19.34MN/AN/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 10/8/2026 by MarketBeat.com Staff.
From Our Partners
China ATTACK on American Dollar set for 11/12/2026
A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...
International Living | Sponsoredtc pixel
“Whoever wins AI, wins”
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
What Could Change After November 3rd?
Democrats are favored to take the House on November 3rd, needing just five seats to flip the chamber. The last...
USA Capital Gold | Sponsoredtc pixel
A dividend every week of the year
Most dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...
Market Savvy | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel